41 in stock
Product name: LGD-4033
Molecular Formula: C14H12F6N2O
Description: LGD-4033 is a brand new SARM that targets the androgen receptors in the muscles to create lean muscle growth and increase strength. LGD-4033 is a non-toxic oral compound with a very strong effectiveness profile and highly promising clinical trial results.
|Bottle:||Premium Ceramic Dropper|
|1 x Bottle LGD-4033 (30ml)|
|Classification||Premium Research Chemicals|
Elite Scientific Analysis:
LGD-4033 (VK5211, Ligandrol) is a brand new selective androgen receptor modulator (SARM) that targets the androgen receptors in the muscles resulting in lean muscle growth and increased strength.
LGD4033 is a non-toxic oral compound with a very strong effectiveness profile and highly promising clinical trial results so far.
It is a non-steroidal, orally administered SARM which binds to the androgen receptor with a high affinity and high selectivity. It demonstrates anabolic activity in muscles as well as anti-resorptive and anabolic activity in bones meaning that it grows and strengthens both of these tissues without adversely affecting surrounding tissue. It exhibits a high selectivity for muscle and bone tissue versus prostate and sebaceous glands unlike testosterone so in many cases this compound produces the therapeutic benefits of testosterone with improved safety and tolerability due to this tissue-selective mechanism.
LGD4033 is currently under development as a treatment for muscle wasting and osteoporosis through the company Viking Therapeutics because of its potential to increase muscle gain and bone strength.
Oral administration of LGD4033 in Macaca fascicularis at daily doses varying from 0 to 75 mg/kg over 13 weeks demonstrated significant body weight gain in both male and female subjects.
In a Phase I clinical trial of 76 adult male humans in which the dose size was varied, a dose-dependent increase in lean body mass was observed with no significant adverse events over the 21 days of the trial. This means that the subjects gained lean muscle without experiencing any negative symptoms and speaks to the potential of this compound to help build body mass.
Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, and QT intervals did not change significantly at any dose in this trial and lean body mass increased dose dependently, but fat mass did not change significantly meaning that the compound builds muscle and bone without also increasing fat deposits.
Hormone levels and lipid levels all returned to baseline after treatment discontinuation.
The Phase 2 clinical trial for LGD4033 currently underway consists of 120 patients recovering from hip fracture surgery. Improved lean body mass is the primary endpoint of this study and it is still ongoing but this compound has the potential to radically improve the quality of patient lives and increase the speed of recovery.
Overall this compound has amazing potential to aid in the development of muscle tissue and bone strength without increasing fat deposits or affecting other tissues in the body. It has the added advantage of aiding the healing process after muscle and bone injury and is a compound with staggering clinical potential.
- Basaria S.,Collins L., Dillon E.L., Orwoll K., Storer T.W., Miciek R., Ulloor J., Zhang A., Eder R., Zientek H., Gordon G.,Kazmi S., Sheffield-Moore M., Bhasin S., The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men, Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2010, 68(1), 87-95.
- Bautz, David, PhD., “VKTX: Additional Preclinical Data Shows Robust and Durable Weight Gain for VK5211-Treated Primates.” VKTX Press Release, 8 Dec. 2015, Online.
- Dressel U., Allen T. L., Pippal J. B., Rohde P. R., Lau P., Muscat, G. E., The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells, Molecular Endocrinology, 2003, 17(12), 2477-2493.